Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Abatacept Infection, Malignancy Risk To Be Considered By Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Arthritis committee is expected to discuss the increased risk of infections when Orencia (abatacept) is used in combination with other biologic rheumatoid arthritis therapies during the Sept. 6 review of Bristol's drug.
Advertisement

Related Content

Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says
Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says
Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol
Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol

Topics

Advertisement
UsernamePublicRestriction

Register

PS062903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel